• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results

    8/8/24 4:05:00 PM ET
    $AXON
    $BIO
    $OCX
    Ordnance And Accessories
    Industrials
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AXON alert in real time by email

    Interest in kidney transplant assay represents approximately 25% of US transplant volume

    Company lays out land and expand strategy in transplant

    IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders.

    Dear shareholders,

    We are thrilled to report that we have successfully launched GraftAssure™, which is our research-use-only assay that can detect early evidence of graft organ damage in a patient's blood.

    On July 11, 2024, our GraftAssure assay was run at a major metropolitan transplant center and research university in the northeast United States, representing the first time our test had been run outside of an Oncocyte lab. Days later, a lab at a leading transplant center in Southeast Asia began running the test.

    Though we believe this milestone is just the beginning, it's an important proof point in an 18-month journey. To recap, in January 2023, we decided to double down on commercializing our transplant test IP, primarily by making a kitted test that relies upon a biomarker, donor-derived cell-free DNA (dd-cfDNA). Our first prototypes of GraftAssure came off the manufacturing line in December. Four months later, in April 2024, we welcomed Bio-Rad Laboratories (NYSE:BIO) as an investor and strategic partner, supporting the GraftAssure global launch.

    And in June 2024, we began shipping to our launch customers. We shipped to two continents in our first week – representing major transplant centers and research universities in the U.S. and Southeast Asia. As of today, we have signed up several centers in the U.S, Europe and Southeast Asia.

    We are also pleased with the momentum we are seeing coming out of the American Transplant Congress in Philadelphia in June. That conference was especially meaningful for Oncocyte this year because it coincided with the New England Journal of Medicine's publication of favorable data regarding our centralized lab product VitaGraft Kidney1. That clinical product uses the same background IP as our GraftAssure kitted test.

    We are pleased to report that our US sales funnel of confirmed interest in our transplant assay is made up of transplant centers that represent approximately 25% of US transplant volumes2. We also are seeing significant interest in Germany, as well as in other European countries, and in Asia and the Middle East. The level of interest and enthusiasm in the market is exceeding our expectations.

    As a reminder, under our partnership, Bio-Rad and Oncocyte are co-marketing GraftAssure inside the US and Germany, with Oncocyte acting as commercial lead. Bio-Rad is acting as commercial lead outside the US and Germany, and correspondingly has been granted exclusive distribution and commercial rights in those countries.

    Beyond growing our sales pipeline, momentum also continues through our industry relationships and partnerships. For example, in the second quarter, we signed an agreement with a European biotechnology company to be the provider of dd-cfDNA testing for a Phase II clinical trial for a therapeutic in antibody mediated rejection.

    Our partnerships with the pharmaceutical industry are strategically important. First, the partnerships highlight and validate the robustness of our technology and our partnership approach to the market. These trials also advance and expand the body of science using our diagnostic technology to develop the potential for new clinical applications for our diagnostic tools.

    Ultimately, the expansion of clinical utility increases the opportunity for future long-term recurring revenue. When we participate in a clinical trial, we perform the services at our clinical (CLIA) laboratory, receiving a nominal amount of revenue to cover the cost of performing the test. While these clinical trials are limited in short-term revenue generation, they lay the foundation for future revenue expansion and growth.

    The dd-cfDNA test that we run at our CLIA laboratory on behalf of customers is VitaGraft Kidney. As a reminder, VitaGraft received Medicare reimbursement in 2023. We are increasing the throughput for VitaGraft in our CLIA lab by establishing higher automation with simple scaling options. This increased capacity supports ongoing clinical trials using our tests and the data generation required by our IVD program, which we discuss further below.

    Transplant: Land & Expand Strategy

    We believe that we are at an inflection point in commercializing our molecular diagnostic tests that can detect early evidence of graft organ damage in the blood. Bringing research centers up online with our GraftAssure assay is a key part of our land-and-expand strategy to drive commercial adoption of our tests and capture market share in an estimated $1 billion total addressable market.

    Simply, our strategy is to land major transplant centers and research universities with our research-use-only product. Doing so establishes our technology and increases its potential utility by enabling researchers to explore potential applications of dd-cfDNA. Then, once we have achieved FDA (Food and Drug Administration) clearance for our test kits to be used to make clinical decisions – that is, approved as an in-vitro diagnostic (IVD) – we believe that these institutions will begin using our tests to manage their patient populations, while continuing to use our GraftAssure test kit to perform research. Importantly, our GraftAssure research product may not be used to support clinical treatment decisions.

    We believe that we can execute upon this strategy with a limited sales force deployed in key territories due to the favorable customer concentration of our industry. For example, fewer than 100 academic and research centers in the US account for about 80% of transplant volumes. And rest-of-world markets are similarly concentrated at high-end academic institutions. Bio-Rad's global infrastructure puts those centers well within reach, allowing for high-touch sales and service at the local level. Partnering into this commercial channel allows Oncocyte to keep our infrastructure costs low while we focus on scaling in manufacturing and developing new use cases. As a result, we believe we have the potential to be more profitable than many larger, better-known diagnostic companies.

    We are seeing early indications of remarkable product-market fit and we are pleased with the market response to our assay. We believe that GraftAssure's appeal is due to workflows that are easy and user-friendly3 and that market enthusiasm will translate to adoption of the IVD product once it is available. We discuss the IVD clearance process in more detail below.

    Our initial beta customers sought to deploy our RUO assay as soon as we could ship it to them – which we find compelling in light of the fact that bringing our RUO assay up and running is a major undertaking for a transplant center's research lab, requiring significant investment of time and resources. It requires performing instrument validation, running an analytical validation study, and training laboratory employees.

    To support the lab's validation process, we ship non-revenue test kits and send a team to support the lab in getting the test up and running, including troubleshooting any initial issues. The first lab to be up and running was able to complete the process in about two weeks, with some initial support from the Oncocyte team until they could run with the assay.

    Our teams ensure the pre-existing equipment is calibrated to support the test and that the customer laboratory teams are trained to run it effectively. Once we've confirmed that the instrument and assay are performing as intended, the labs begin running their first research samples and preparing to launch new studies. Most of the customers in our funnel come to us with studies in mind that they've wanted to do for a long time and are excited that they'll get a chance to move forward on their own.

    Notably, some of these centers are eager to support the development of our IVD product. Whether collecting samples or producing data, the clinical researchers are excited to work with us on this process. Our openly collaborative approach is winning hearts and minds across the industry. We take our commitments and responsibility to the research community very seriously – they use our tests to advance the body of science in transplant medicine, which may save many lives over time.

    We aim to have more than 20 transplant centers running GraftAssure tests through the end of 2025, including 15 in the US. We estimate that each center represents an eventual annual high-margin revenue stream of several hundred thousand dollars to $2 million, depending on the size of the center.

    The following illustration shows a projected quarterly revenue path for one typical beta customer. The illustration shows the customer entering 2028 contributing $400,000 in quarterly revenue, or $1.6 million in annual run rate revenue. Importantly, this revenue path assumes our best-case timeline4 for FDA clearance of the IVD product for clinical use in late 2025 and a MolDX5 reimbursement decision attached to the IVD product in early 2026.

    Beta Costumer Revenue Path

    What's next:

    • Continued roll-out of research product: We will continue to bring transplant center customers up online running our GraftAssure assay throughout 2024 and 2025.
    • Impact of legislation: We believe our timing is serendipitous as the Increasing Organ Transplant Access Model, by the Centers for Medicare and Medicaid Services, rolls out on January 1, 2025. Transplant surgeons have told us that they expect that this legislation will lead to more marginal organs being transplanted into patients and potentially higher rates of adverse events, which could increase demand for dd-cfDNA testing. As a reminder, our IVD strategy aims to empower transplant centers to perform dd-cfDNA tests in-house and submit for reimbursement for their own labs.
    • Q-Sub submission: The Q-Sub process is a formal procedure in which a company submits a validation plan to the FDA for review and receives their feedback. We hope to receive feedback from the FDA by the end of 2024. We need this feedback to move forward with confidence into our clinical validation processes prior to submitting for FDA IVD clearance next year.
    • FDA IVD-clearance process: Medical devices are classified into three categories based on their risk – our tests are considered Class II devices, meaning that they are considered to have a moderate level of risk6 to the patient. We will submit under the 510(k) De Novo Classification process, which is premarket submission made to the FDA for a new "device," or in our case, test. We are aiming to achieve FDA clearance in late 2025, which is our best-case timeline. Below are some of the data points that give us confidence going into this process.
      • The successful launch of GraftAssure, and the resulting engagement that we are having with the community, supports our IVD product development efforts. Many of the sites that are in our funnel have expressed interest in collecting samples and potentially being a reproducibility site to support our ultimate submission to the FDA.
      • We have found recent dialogue with the FDA to be constructive. We look forward to more interactions throughout the year in the formal Q-Sub process described above.
      • Key members of our team have deep FDA regulated product experience.7
      • We have deep technical and clinical expertise in transplant, with a greater-than-ten-year track record of developing innovative technology and publishing novel data. It's a history that compares favorably to any other player in the transplant rejection diagnostics space.
        • Examples include:
          • Patents granted in both the US and EU support the technical innovation core to the IVD development process, protecting our market opportunity.
          • MolDX8 cited our publications twice when it established the LCD (Local Coverage Determination) for Medicare and Medicaid reimbursement coverage for cell free DNA testing.
          • In the New England Journal of Medicine publication referenced above, we are the first company to have published randomized interventional data showing the efficacy of a transplant rejection diagnostic test along with antibody mediated rejection (AMR) therapy.
          • We are also the only company to have randomized interventional clinical trial data using dd-cfDNA to detect AMR in de novo DSA+ (donor-specific antibody positive) kidney patients, finding AMR 10 months sooner9 than other monitoring protocols.
      • Our manufacturing partner has significant experience in the production of regulated products for both US and global distribution, and the ability to scale to meet global demand.

    New CFO Appointed

    In preparation for the next several years of sustained, rapid growth, we welcomed Andrea James as Chief Financial Officer in June. She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors.

    Prior to joining Oncocyte, Andrea served as chief communications officer and head of investor relations at Axon Enterprise, Inc. (NASDAQ:AXON). She joined Axon's finance team in 2017 to build the company's investor relations function and played an integral role through the company's growth from $1 billion in market capitalization to a company valued at more than $20 billion. She led Axon's repositioning as a top-tier technology company with the investment community and established Axon's corporate strategy function, overseeing capital stewardship, mergers and acquisitions, strategic partnerships and investments. Her work was instrumental in supporting more than $550 million in equity capital offerings.

    Prior to Axon, Andrea worked in a strategic investor relations role for Tesla, Inc., in 2016 and 2017. From 2009 to 2016 she worked as a sell-side analyst for Dougherty & Company (now Colliers Securities), becoming a vice president and senior research analyst. At Dougherty, she researched emerging technologies on behalf of institutional investors. Previously, she was a reporter at publications including Bloomberg News and the Seattle Post-Intelligencer covering a range of business and financial beats. She holds a Bachelor of Science, summa cum laude, in Computer Information Systems from American University. She also holds a Master of Science in Journalism from Northwestern University, graduating with Kappa Tau Alpha honors. While at Dougherty, her Financial Industry Regulatory Authority (FINRA) licenses included the Series 7, 86, 87 and 63.

    Q2 2024 Financial Overview

    • Revenue of $104,000 in the second quarter was derived from pharma services performed in Nashville.
    • A gross profit of $50,000 reflected the relatively fixed costs of operating our Nashville CLIA laboratory. These costs include labor as well as infrastructure expenses such as the depreciation of laboratory equipment, allocated rent costs, leasehold improvements, and allocated information technology costs.
    • Operating expenses of $4.7 million included $386,000 in non-cash stock-based compensation expenses, $326,000 in non-cash depreciation and amortization expenses and a $1.0 million non-cash benefit from the change in fair value of contingent consideration. Excluding these non-cash items in the current and prior periods, our Q2 operating expenses decreased approximately 5% sequentially and decreased 9% year over year.
    • Research and development expense of $2.5 million increased approximately 6% sequentially.
    • Sales and marketing expense of $853,000 was flat sequentially, reflecting cost discipline even as we began to ramp the commercialization of our transplant tests.
    • General and administrative expense of $2.4 million fell 10% sequentially, reflecting cost discipline and reductions in facilities and personnel related costs.
    • Loss from continuing operations was $4.5 million, or $0.36 per share.
    • Non-GAAP loss from operations was $5.0 million and excludes certain non-cash items. Please refer to the table below, "Reconciliation of Non-GAAP Financial Measure," for additional information.
    • Oncocyte's cash, cash equivalents, and restricted cash balance at the end of the second quarter was approximately $11.0 million, up $3.7 million sequentially. This balance includes proceeds from our capital raised in April as well as $1.7 million in restricted cash.
      • On April 11, 2024, we entered into a private placement securities purchase agreement with certain accredited investors. The resulting net proceeds were approximately $9.9 million, after deducting offering expenses of $539,000 and deducting $5.4 million for the redemption of all remaining shares of our Series A Redeemable Convertible Preferred Stock. These proceeds include the investment from Bio-Rad. We are pleased to be entering a growth inflection point with a streamlined capital structure.
      • Cash flows from operations reflected $1.4 million in bonus and retention payments made to employees in the second quarter, mostly as part of our annual compensation cycle.

    New investor deck published

    New Investor Deck

    To view our quarterly update in the context of our larger strategy, you may access a refreshed investor deck at investors.oncocyte.com or access it at: https://investors.oncocyte.com/~/media/Files/O/Oncocyte-IR/events-and-presentations/ocx-investor-deck-q2-2024.pdf.

    In the deck, we outline our innovation flywheel and provide more details on our land and expand strategy, with key upcoming milestones and catalysts.

    Conclusion

    We are pleased to be delivering upon our commitments and are thrilled with our market momentum. After months of effort, we are seeding the market with our RUO product – which is the first step in our land and expand strategy. And we believe that we already have clear signs of remarkable product-market fit.

    Our mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. We believe that combining innovative science with a simple and disruptive business model can create enormous societal and shareholder value.

    We look forward to welcoming you on our growth journey and updating you on our continued progress throughout the year.

    The Oncocyte Management Team

    Webcast and Conference Call Information:

    Conference Call and Webcast on Thursday, August 8, 2024, at 2:00 p.m. PT / 5:00 p.m. ET

    You may access the live call via telephone by dialing toll-free 800-715-9871 for domestic callers. Once dialed in, ask to be joined to the Oncocyte Corporation call.

    The live webcast of the call may be accessed by visiting the "Events & Presentations" section of the Company's website at https://investors.oncocyte.com. A replay of the webcast will be available on the Company's website.

    CONFERENCE CALL DETAILS


    Participant Toll-Free Dial-In Number: (800) 715-9871

    Participant Toll Dial-In Number: +1 (646) 307-1963

    Conference ID: 4153469

    Webcast

    https://events.q4inc.com/attendee/478523544

    About Oncocyte

    Oncocyte is a molecular diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:

    VitaGraft Kidney™ - https://oncocyte.com/vitagraft-kidney/


    VitaGraft Liver™ - https://oncocyte.com/vitagraft-liver/


    GraftAssure™ - https://oncocyte.com/graftassure/


    DetermaIO™ - https://oncocyte.com/determa-io/


    DetermaCNI™ - https://oncocyte.com/determa-cni/

    VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

    Forward-Looking Statements

    Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things, future expansion and growth, the Company's land-and-expand strategy to drive commercial adoption of its tests and capture market share, plans to have transplant centers running GraftAssure tests through the end of 2025, projected revenue path, IVD strategy, assumptions regarding regulatory approvals and clearances, timing and planned regulatory submissions, and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

    CONTACT:

    Jeff Ramson

    PCG Advisory


    (646) 863-6893


    [email protected]

    - Tables Follow -

    ONCOCYTE CORPORATION

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except per share data)
     
        
     June 30, December 31,
      2024   2023 
     (Unaudited)  
    ASSETS   
    CURRENT ASSETS   
    Cash and cash equivalents$9,256  $9,432 
    Accounts receivable, net of allowance for credit losses of $1 and $5, respectively 85   484 
    Prepaid expenses and other current assets 595   643 
    Assets held for sale 32   139 
    Total current assets 9,968   10,698 
        
    NONCURRENT ASSETS   
    Right-of-use and financing lease assets, net 2,591   1,637 
    Machinery and equipment, net, and construction in progress 3,347   3,799 
    Intangible assets, net 56,551   56,595 
    Restricted cash 1,700   1,700 
    Other noncurrent assets 563   463 
    TOTAL ASSETS$74,720  $74,892 
        
    LIABILITIES AND SHAREHOLDERS' EQUITY   
    CURRENT LIABILITIES   
    Accounts payable$1,051  $953 
    Accrued compensation 1,309   1,649 
    Accrued royalties 1,116   1,116 
    Accrued expenses and other current liabilities 379   452 
    Accrued severance from acquisition 2,314   2,314 
    Right-of-use and financing lease liabilities, current 1,029   665 
    Current liabilities of discontinued operations -   45 
    Total current liabilities 7,198   7,194 
        
    NONCURRENT LIABILITIES   
    Right-of-use and financing lease liabilities, noncurrent 2,638   2,204 
    Contingent consideration liabilities 42,181   39,900 
        
    TOTAL LIABILITIES 52,017   49,298 
        
    Commitments and contingencies   
        
    Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 5 shares issued and outstanding at December 31, 2023; aggregate liquidation preference of $5,296 as of December 31, 2023 -   5,126 
        
    SHAREHOLDERS' EQUITY   
    Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding -   - 
    Common stock, no par value, 230,000 shares authorized; 13,368 and 8,261 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 326,201   310,295 
    Accumulated other comprehensive income 37   49 
    Accumulated deficit (303,535)  (289,876)
    Total shareholders' equity 22,703   20,468 
    TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$74,720  $74,892 
        

     

    ONCOCYTE CORPORATION

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (In thousands, except per share data)
            
     Three Months Ended

    Six Months Ended

     June 30,

     June 30,

      2024   2023   2024   2023 
            
    Net revenue$104  $463  $280  $760 
            
    Cost of revenues 32   169   141   434 
    Cost of revenues – amortization of acquired intangibles 22   22   44   44 
    Gross profit 50   272   95   282 
            
    Operating expenses:       
    Research and development 2,453   2,435   4,765   4,562 
    Sales and marketing 853   805   1,699   1,500 
    General and administrative 2,407   3,531   5,080   6,943 
    Change in fair value of contingent consideration (1,031)  1,795   2,281   (16,512)
    Impairment loss -   -   -   4,950 
    Impairment loss on held for sale assets -   -   169   1,283 
    Total operating expenses 4,682   8,566   13,994   2,726 
            
    Loss from operations (4,632)  (8,294)  (13,899)  (2,444)
            
    Other (expenses) income:       
    Interest expense (8)  (14)  (23)  (25)
    Unrealized (loss) gain on marketable equity securities -   (24)  -   97 
    Other income (expenses), net 110   (1)  263   (2)
    Total other income (expenses) 102   (39)  240   70 
            
    Loss from continuing operations (4,530)  (8,333)  (13,659)  (2,374)
            
    Loss from discontinued operations -   -   -   (2,926)
            
    Net loss$(4,530) $(8,333) $(13,659) $(5,300)
            
    Net loss per share:       
    Net loss from continuing operations - basic and diluted$(4,587) $(8,644) $(13,922) $(2,915)
    Net loss from discontinued operations - basic and diluted$-  $-  $-  $(2,926)
    Net loss attributable to common stockholders - basic and diluted$(4,587) $(8,644) $(13,922) $(5,841)
            
    Net loss from continuing operations per share - basic and diluted$(0.36) $(1.07) $(1.32) $(0.41)
    Net loss from discontinued operations per share - basic and diluted$-  $-  $-  $(0.42)
    Net loss attributable to common stockholders per share - basic and diluted$(0.36) $(1.07) $(1.32) $(0.83)
            
    Weighted average shares outstanding - basic and diluted 12,870   8,090   10,567   7,030 
            

     

     ONCOCYTE CORPORATION

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In thousands)
            
     Three Months Ended

    Six Months Ended

     June 30,

     June 30,

      2024   2023   2024   2023 
            
    CASH FLOWS FROM OPERATING ACTIVITIES:       
    Net loss$(4,530) $(8,333) $(13,659) $(5,300)
    Adjustments to reconcile net loss to net cash used in operating activities:       
    Depreciation and amortization expense 304   435   617   885 
    Amortization of intangible assets 22   22   44   44 
    Stock-based compensation 386   834   804   1,668 
    Equity compensation for bonus awards and consulting services 50   -   96   - 
    Unrealized gain on marketable equity securities -   24   -   (97)
    Change in fair value of contingent consideration (1,031)  1,795   2,281   (16,512)
    Impairment loss -   -   -   4,950 
    Loss on disposal of discontinued operations -   -   -   1,521 
    Impairment loss on held for sale assets -   -   169   1,283 
    Changes in operating assets and liabilities: -   -     
    Accounts receivable 76   185   399   296 
    Prepaid expenses and other assets 12   (52)  (50)  567 
    Accounts payable and accrued liabilities (1,240)  (1,657)  (386)  (4,319)
    Lease assets and liabilities (27)  (85)  (123)  (118)
    Net cash used in operating activities (5,978)  (6,832)  (9,808)  (15,132)
            
    CASH FLOWS FROM INVESTING ACTIVITIES:       
    Proceeds from sale of equipment -   123   -   123 
    Construction in progress and purchases of furniture and equipment (191)  -   (215)  - 
    Cash sold in discontinued operations -   -   -   (1,372)
    Net cash used in investing activities (191)  123   (215)  (1,249)
            
    CASH FLOWS FROM FINANCING ACTIVITIES:       
    Proceeds from sale of common shares 15,807   13,848   15,807   13,848 
    Financing costs to issue common shares (538)  (427)  (538)  (427)
    Redemption of redeemable convertible Series A preferred shares (5,389)  (1,118)  (5,389)  (1,118)
    Repayment of financing lease obligations (33)  (29)  (33)  (57)
    Net provided by financing activities 9,847   12,274   9,847   12,246 
            
    NET CHANGE IN CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH 3,678   5,565   (176)  (4,135)
            
    CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, BEGINNING 7,278   13,503   11,132   23,203 
    CASH, CASH EQUIVALENTS (INCLUDES DISCONTINUED OPERATIONS) AND RESTRICTED CASH, ENDING$10,956  $19,068  $10,956  $19,068 
            
            

     

    Oncocyte Corporation

    Reconciliation of Non-GAAP Financial Measure

    Consolidated Adjusted Loss from Operations
     
    Note: In addition to financial results determined in accordance with U.S. generally accepted accounting principles ("GAAP"), this press release also includes a non-GAAP financial measure (as defined under SEC Regulation G). We believe the adjusted amounts are more representative of our ongoing performance. The following is a reconciliation of the non-GAAP measure to the most directly comparable GAAP measure:
     
     Three Months Ended
     June 30, March 31, June 30,
      2024   2024   2023 
      (unaudited)   (unaudited)   (unaudited) 
     (In thousands)
    Consolidated GAAP loss from operations$ (4,632) $ (9,267) $ (8,294)
    Stock-based compensation 386   418   816 
    Depreciation and amortization expense 326   335   457 
    Change in fair value of contingent consideration (1,031)  3,312   1,795 
    Impairment losses -   -   - 
    Impairment loss on held for sale assets -   169   - 
    Consolidated Non-GAAP loss from operations, as adjusted$ (4,951) $ (5,033) $ (5,226)
          

    1 Oncocyte's Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study (NCT05021484) of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.

    2 The centers in our U.S. funnel who have confirmed interest in GraftAssure represent more than 11,000 transplants per year, which is about 24% of 46,000 annual transplants conducted, according to the United Network for Organ Sharing. (Source: https://unos.org/about/fast-facts/#:~:text=In%202023%3A,continuing%20annual%20record%2Dsetting%20trend)

    3 Bio-Rad's QX600 Droplet Digital PCR (ddPCR) System – which is its new six color instrument – allows us to create a simple workflow for the lab technician, delivering a result in four to eight hours, compared with ≥30 hours for competitors that are using NGS technology. Further, testing a single sample is an affordable option, given that the batch size – in contrast to NGS – does not alter the price per result.

    4 The revenue build is purposely limited in scope to the current clinical utility established for VitaGraft Kidney. Incremental revenue opportunities could come from additional claims, such as additional tissue types like heart and lung, anti-CD38 drug monitoring, and high-risk patient monitoring. Notably, our best-case FDA clearance timeline should not be confused with our best-case revenue opportunity.

    5 MolDX is a program that identifies and establishes coverage and U.S. government reimbursement for molecular diagnostic tests.

    6 An example of a Class I, or low risk, device, would be a bandage and an example of a Class III, or high risk, device would be an implantable device like a cardiac pacemaker.

    7 As an example, our Chief Technology Officer, Johnson Chiang, has successfully led or participated in numerous IVD submissions to the US FDA and the EU under IVDD

    8 Source: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38671&ver=4

    9 For more information: https://investors.oncocyte.com/news-releases/2023/09-18-2023

    Images accompanying this announcement are available at

    https://www.globenewswire.com/NewsRoom/AttachmentNg/3d35970e-bf96-46e3-8332-a3bb4be502da

    https://www.globenewswire.com/NewsRoom/AttachmentNg/d81dce54-0028-4dc0-892c-36bf67648d0d



    Primary Logo

    Get the next $AXON alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AXON
    $BIO
    $OCX

    CompanyDatePrice TargetRatingAnalyst
    Axon Enterprise Inc.
    $AXON
    7/8/2025Outperform
    Wolfe Research
    Oncocyte Corporation
    $OCX
    3/28/2025$5.00Buy
    Lake Street
    Axon Enterprise Inc.
    $AXON
    2/20/2025$625.00Buy → Hold
    Craig Hallum
    Axon Enterprise Inc.
    $AXON
    2/19/2025Buy → Neutral
    Northcoast
    Axon Enterprise Inc.
    $AXON
    1/8/2025$700.00Buy
    TD Cowen
    Axon Enterprise Inc.
    $AXON
    12/3/2024$500.00 → $700.00Equal-Weight → Overweight
    Morgan Stanley
    Bio-Rad Laboratories Inc.
    $BIO
    10/1/2024$350.00 → $400.00Neutral → Buy
    Citigroup
    Axon Enterprise Inc.
    $AXON
    9/12/2024$375.00 → $430.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $AXON
    $BIO
    $OCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Arno Andrew was granted 55,000 shares, increasing direct ownership by 67% to 136,554 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:25 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Silverman Lou was granted 35,000 shares, increasing direct ownership by 2,238% to 36,564 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:34 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Last Andrew J. was granted 35,000 shares, increasing direct ownership by 776% to 39,509 units (SEC Form 4)

      4 - Insight Molecular Diagnostics Inc. (0001642380) (Issuer)

      7/3/25 4:05:22 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AXON
    $BIO
    $OCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wolfe Research initiated coverage on Axon

      Wolfe Research initiated coverage of Axon with a rating of Outperform

      7/8/25 8:45:23 AM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • Lake Street initiated coverage on OncoCyte with a new price target

      Lake Street initiated coverage of OncoCyte with a rating of Buy and set a new price target of $5.00

      3/28/25 8:35:58 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Axon downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Axon from Buy to Hold and set a new price target of $625.00

      2/20/25 8:17:48 AM ET
      $AXON
      Ordnance And Accessories
      Industrials

    $AXON
    $BIO
    $OCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer James Andrea S. bought $200,000 worth of shares (97,561 units at $2.05), increasing direct ownership by 182% to 151,231 units (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 7:00:32 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Smith Patrick W bought $2,209,080 worth of shares (1,077,600 units at $2.05) and acquired $790,919 worth of shares (385,814 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/11/25 5:00:15 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Large owner Broadwood Partners, L.P. bought $10,589,675 worth of shares (5,165,695 units at $2.05) (SEC Form 4)

      4 - Oncocyte Corp (0001642380) (Issuer)

      2/10/25 8:43:04 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $AXON
    $BIO
    $OCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet Digital™ PCR (ddPCR™) platforms. The newly introduced instruments include Bio-Rad's QX Continuum™ ddPCR system along with the QX700™ series of ddPCR platforms acquired as part of the company's recently completed acquisition of digital PCR developer Stilla Technologies. Together with Bio-Rad's existing line of QX200™ and QX600™ ddPCR systems, the expanded product portfolio, including over 400,000 assays, offers the most comprehensive line of digital PCR products for life science research and diagnostic applications. The end-to-end

      7/7/25 9:00:00 AM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

      New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globallyExhibiting at European Society of Organ Transplantation (ESOT) conference in London, June 29 – July 2, 2025 NASHVILLE, Tenn., June 17, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. ("iMDx" or the "Company"), (NASDAQ:IMDX), formerly known as Oncocyte Corporation (NASDAQ:OCX), has announced its renaming and the relocation of its principal executive office from Irvine, California, to Nashville, Tennessee. The Company's common stock, listed on the Nasdaq Capital Market, will begin trading

      6/17/25 7:00:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Operating Officer Jon DiVincenzo will host one-on-one meetings with investors during the Jefferies Global Healthcare Conference in New York City, on June 4, 2025. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE:BIO) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 7,500 employees, and $2.6 billion in reve

      5/29/25 4:30:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXON
    $BIO
    $OCX
    SEC Filings

    See more
    • Oncocyte Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Insight Molecular Diagnostics Inc. (0001642380) (Filer)

      7/2/25 5:01:52 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Oncocyte Corp (0001642380) (Filer)

      6/17/25 7:33:46 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Axon Enterprise Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - AXON ENTERPRISE, INC. (0001069183) (Filer)

      6/2/25 4:13:22 PM ET
      $AXON
      Ordnance And Accessories
      Industrials

    $AXON
    $BIO
    $OCX
    Leadership Updates

    Live Leadership Updates

    See more
    • Veradigm Announces Board Expansion and Changes

      Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

      2/20/25 4:02:00 PM ET
      $MDRX
      $OCX
      $ZIMV
      EDP Services
      Technology
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

      Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ:OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company's Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and clinical goals for Oncocyte. Dr. Billings is a recognized pioneer in genomics and precision medicine with over 40 years of experience spanning academia, government,

      1/8/25 8:30:00 AM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXON
    $BIO
    $OCX
    Financials

    Live finance-specific insights

    See more
    • Oncocyte to Release First Quarter 2025 Results on May 12, 2025

      IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: Oncocyte Q1 2025 Earnings Webinar. An archived replay will be available after the call concludes on Oncocyte's investor relations website at https://investors.oncocyte.com. About Oncocyte Oncocyte is a pioneering di

      5/7/25 4:10:00 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Axon reports Q1 2025 revenue of $604 million, up 31% year over year

      SCOTTSDALE, Ariz., May 7, 2025 /PRNewswire/ -- Software & Services revenue grows 39% to $263 millionAnnual recurring revenue grows 34% to $1.1 billionNet income of $88 million supports non-GAAP net income of $115 million and Adjusted EBITDA of $155 millionRaises full year revenue outlook to a range of $2.60 billion to $2.70 billion, up from $2.55 billion to $2.65 billion Fellow shareholders, Axon delivered a strong start to 2025, achieving record quarterly revenue while maintaining healthy margins and reinforcing our foundation for long-term growth through continued product in

      5/7/25 4:01:00 PM ET
      $AXON
      Ordnance And Accessories
      Industrials
    • Bio-Rad Reports First-Quarter 2025 Financial Results

      Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "We navigated a highly dynamic first quarter that became progressively more challenging, yet we delivered solid margins through focused execution and careful expense management. Given the current levels of market uncertainty, we are moderating our full-year 2025 outlook to reflect the evolving macro environment. Going forward, we remain committed to advancing our growth and margin expansion initiatives." Financial Results Highl

      5/1/25 4:15:00 PM ET
      $BIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXON
    $BIO
    $OCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      12/9/24 5:30:06 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Oncocyte Corporation

      SC 13G - Oncocyte Corp (0001642380) (Subject)

      11/14/24 1:26:16 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oncocyte Corporation

      SC 13G/A - Oncocyte Corp (0001642380) (Subject)

      10/24/24 12:13:28 PM ET
      $OCX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care